$FTV earnings report

Fortive Reports Third Quarter 2026 Results. AlphAI read Fortive's Third Quarter 2026 filing as strong. 2 quarters are on record below.

Third Quarter 2026

AlphAI · Earnings readFTV · Third Quarter 2026 · ended October 2, 2026

Fortive Reports Third Quarter 2026 Results

✓Strong quarter

Q3 revenue grew 7.8% reported and 7.2% on a core basis, adjusted EBITDA increased 9.5%, adjusted diluted EPS increased 13.2%, and Fortive raised FY 2026 adjusted diluted EPS guidance to $3.10 to $3.14.

Revenue
$1.11B
7.8% y/y
Intelligent Operating Solutions
$767M
9.8% / 9.1% (reported / core) y/y
Operating margin · GAAP
21.3 %
EPS · non-GAAP
$0.77
13.2% y/y

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Q3 2026 revenueGAAP$1.11B–7.8%
Q3 2026 core revenue growthnon-GAAP7.2%–7.2%
Q3 2026 gross profitGAAP$710.6M––
Q3 2026 operating profitGAAP$235.9M––
Q3 2026 operating marginGAAP21.3 %––
Q3 2026 net earnings from continuing operationsGAAP$173M–47.4%
Q3 2026 GAAP net earnings marginGAAP15.6%–420 bps
Q3 2026 adjusted EBITDAnon-GAAP$339M–9.5%
Q3 2026 adjusted EBITDA marginnon-GAAP30.6%–50 bps
Q3 2026 diluted earnings per share from continuing operationsGAAP$0.57–62.9%
Q3 2026 adjusted diluted earnings per share from continuing operationsnon-GAAP$0.77–13.2%
Q3 2026 operating cash flow from continuing operationsGAAP$313M–6.3%
Q3 2026 free cash flow from continuing operationsnon-GAAP$284M–6.7%
Trailing twelve months GAAP operating cash flow from continuing operationsGAAP$1.18B–15.5%
Trailing twelve months free cash flow from continuing operationsnon-GAAP$1.06B–15.2%
Nine months ended October 2, 2026 salesGAAP$3.27B––
Nine months ended October 2, 2026 gross profitGAAP$2.08B––
Nine months ended October 2, 2026 operating profitGAAP$637.5M––
Nine months ended October 2, 2026 net earnings from continuing operationsGAAP$466.2M––
Nine months ended October 2, 2026 diluted earnings per share from continuing operationsGAAP$ 1.51––
Nine months ended October 2, 2026 net cash provided by operating activitiesGAAP$834.2M––

Segments

SegmentRevenueq/qy/y
Intelligent Operating SolutionsRevenue growth was reported as 9.8% and core revenue growth was 9.1%; GAAP operating margin was 29.1% and adjusted EBITDA margin was 35.8%.$767M–9.8% / 9.1% (reported / core)
Advanced Healthcare SolutionsRevenue growth was reported as 3.7% and core revenue growth was 3.1%; GAAP operating margin was 11.2% and adjusted EBITDA margin was 25.8%.$340M–3.7% / 3.1% (reported / core)

FY 2026 outlook

  • NoteAdjusted diluted earnings per share of $3.10 to $3.14

Capital returns

  • Deployed ~$300 million towards share repurchases in Q3, representing ~5 million shares or ~2% of diluted shares outstanding.
  • Completed ~$300 million of share repurchases in Q3, bringing total share repurchases since the launch of new Fortive to ~$2.3 billion, representing ~43 million shares or ~13% of shares outstanding.
  • Repurchase of common shares was $(1,000.4) million for the nine months ended October 2, 2026.
  • Payment of dividends was $(57.3) million for the nine months ended October 2, 2026.

What drove it

  • Total Q3 revenue growth was 7.8% reported and 7.2% core.
  • Intelligent Operating Solutions produced $767M of revenue, with 9.1% core revenue growth.
  • Fortive cited investments in innovation acceleration, commercial acceleration, and recurring customer value as contributors to faster revenue growth and financial performance.
  • Q3 adjusted EBITDA growth was 9.5%, and adjusted diluted EPS growth was 13.2%.
  • The company recorded a recovery within cost of sales for IEEPA tariff refund claims accepted by U.S. Customs and Border Protection; pretax IEEPA tariff refunds were $(18.0) million in the adjusted EBITDA reconciliation.

Concerns

  • Advanced Healthcare Solutions revenue grew 3.7% reported and 3.1% core, below Intelligent Operating Solutions growth.
  • Advanced Healthcare Solutions GAAP operating profit declined (10.1)% to $38M, adjusted EBITDA declined (4.8)% to $88M, and adjusted EBITDA margin declined (230) bps to 25.8%.
  • Interest expense, net was $ 38.8 million in Q3 2026 compared with $ 25.4 million in Q3 2025.
  • Long-term debt was $ 3,514.2 million as of October 2, 2026, compared with $ 2,306.5 million as of December 31, 2025.

What to watch

  • Delivery against FY 2026 adjusted diluted EPS guidance of $3.10 to $3.14.
  • Whether Intelligent Operating Solutions sustains 9.1% core revenue growth.
  • Advanced Healthcare Solutions revenue growth and recovery in GAAP and adjusted EBITDA margins.
  • The effect of the IEEPA tariff-refund recovery and capitalized software impairment on reported and adjusted results.
  • Further share repurchases following ~$2.3 billion repurchased since the launch of new Fortive.

Balance sheet and cash flow

  • Cash and equivalents were $ 377.3 million as of October 2, 2026, compared with $ 375.5 million as of December 31, 2025.
  • Long-term debt was $ 3,514.2 million as of October 2, 2026, compared with $ 2,306.5 million as of December 31, 2025.
  • Current portion of long-term debt was $ — as of October 2, 2026, compared with $ 899.5 million as of December 31, 2025.
  • Nine-month net cash provided by operating activities was $ 834.2 million, compared with $ 717.3 million.
  • Nine-month purchases of property, plant and equipment were $(84.2) million, compared with $(74.7) million.
  • Nine-month cash paid for acquisitions, net of cash received was $(58.1) million.
  • Nine-month proceeds from borrowings, net of issuance costs, were $ 1,088.0 million, while repayment of borrowings was $(1,192.9) million.

Analysis

Fortive reported Q3 2026 revenue of $1.11 billion, up 7.8% year-over-year on a reported basis and 7.2% on a core basis. Intelligent Operating Solutions was the primary growth contributor, with $767M of revenue and 9.1% core growth. Advanced Healthcare Solutions generated $340M of revenue, with 3.1% core growth. The company characterized the quarter as its fifth consecutive quarter of double-digit adjusted EPS growth.

Profitability improved at the consolidated level. GAAP net earnings from continuing operations increased 47.4% to $173M, GAAP net earnings margin rose 420 bps to 15.6%, and adjusted EBITDA increased 9.5% to $339M. Adjusted EBITDA margin rose 50 bps to 30.6%. GAAP diluted EPS increased 62.9% to $0.57, while adjusted diluted EPS increased 13.2% to $0.77. The reconciliation includes $(18.0) million of pretax IEEPA tariff refunds and $6.2 million of pretax capitalized software impairment in Q3 2026.

Segment margins diverged. Intelligent Operating Solutions increased GAAP operating margin by 320 bps to 29.1% and adjusted EBITDA margin by 120 bps to 35.8%. Advanced Healthcare Solutions reported a 170 bps decline in GAAP operating margin to 11.2% and a 230 bps decline in adjusted EBITDA margin to 25.8%; its GAAP operating profit and adjusted EBITDA both declined year-over-year. This segment profitability trend is the principal counterweight to the consolidated growth and margin performance.

Cash generation remained positive, with Q3 GAAP operating cash flow of $313M and free cash flow of $284M. Trailing twelve months GAAP operating cash flow was $1,177M and free cash flow was $1,062M. Fortive deployed ~$300 million to Q3 share repurchases, while nine-month repurchases totaled $(1,000.4) million and dividend payments totaled $(57.3) million. Cash and equivalents were $377.3 million and long-term debt was $3,514.2 million at October 2, 2026.

Management raised FY 2026 adjusted diluted EPS guidance to $3.10 to $3.14 and did not provide revenue, margin, operating-expense, or tax-rate guidance in the release. The guide reflects management's stated confidence in the business trajectory and year-to-date results. With no previous outlook supplied, performance versus prior guidance cannot be assessed from the provided documents.

Management, verbatim

Q3 was another quarter of strong and accelerating performance for Fortive. We delivered over 7% core growth, approximately 10% adjusted EBITDA growth, and 13% adjusted EPS growth, representing our fifth consecutive quarter of double-digit adjusted EPS growth.

Olumide Soroye, President and CEO

We are raising our full-year adjusted EPS guidance to $3.10 to $3.14, reflecting our strong year-to-date performance and our confidence in the trajectory of the business.

Olumide Soroye, President and CEO

Not in the filing

stated, not guessed
  • Previous-release outlook was not provided; therefore, no comparison of actual results with prior guidance is available.
  • FY 2026 revenue guidance was not provided.
  • FY 2026 gross-margin guidance was not provided.
  • FY 2026 operating-expense guidance was not provided.
  • FY 2026 tax-rate guidance was not provided.
  • Q3 2026 gross margin was not provided.
  • Q3 2026 prior-quarter comparisons and sequential changes for reported metrics were not provided.
  • Q3 2026 GAAP effective tax rate was not provided.
  • A Q3 2026 adjusted net earnings year-over-year percentage change was not provided.
  • A Q3 2026 total GAAP operating-profit year-over-year percentage change was not provided.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Q2 FY2026

AlphAI · Earnings readFTV · Q2 2026

Fortive Reports Second Quarter 2026 Results

✓Strong quarter

Revenue grew 7.9% year-over-year on a reported basis and 6.7% on a core basis, while GAAP net earnings rose 40.9%, adjusted EBITDA rose 12.0%, adjusted diluted EPS rose 28.5%, and the company raised FY 2026 adjusted diluted EPS guidance to $2.95 to $3.05.

Revenue
$1.10B
7.9% y/y
Intelligent Operating Solutions
$758M
8.8% / 7.4% (reported / core) y/y
Operating margin · GAAP
26.8%
230 bps y/y
EPS · non-GAAP
$0.74
28.5% y/y

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
RevenueGAAP$1.10B–7.9%
Core revenue growthnon-GAAP6.7%–6.7%
GAAP net earningsGAAP$157M–40.9%
GAAP net earnings marginGAAP14.3%–330 bps
Adjusted EBITDAnon-GAAP$323M–12.0%
Adjusted EBITDA marginnon-GAAP29.5%–110 bps
GAAP diluted earnings per shareGAAP$0.51–54.5%
Adjusted diluted earnings per sharenon-GAAP$0.74–28.5%
GAAP operating cash flowGAAP$299M–45.7%
Free cash flownon-GAAP$271M–50.3%
TTM GAAP operating cash flowGAAP$1.16B–12.5%
TTM free cash flownon-GAAP$1.04B–11.2%
Intelligent Operating Solutions GAAP operating profitGAAP$204M–19.1%
Intelligent Operating Solutions GAAP operating marginGAAP26.8%–230 bps
Intelligent Operating Solutions adjusted EBITDAnon-GAAP$264M–12.2%
Intelligent Operating Solutions adjusted EBITDA marginnon-GAAP34.9%–110 bps
Advanced Healthcare Solutions GAAP operating profitGAAP$38M–7.0%
Advanced Healthcare Solutions GAAP operating marginGAAP11.3%–10 bps
Advanced Healthcare Solutions adjusted EBITDAnon-GAAP$88M–2.7%
Advanced Healthcare Solutions adjusted EBITDA marginnon-GAAP26.1%–(80) bps

Segments

SegmentRevenueq/qy/y
Intelligent Operating SolutionsRevenue increased on both a reported and core basis.$758M–8.8% / 7.4% (reported / core)
Advanced Healthcare SolutionsRevenue increased on both a reported and core basis.$339M–6.0% / 5.3% (reported / core)

FY 2026 outlook

  • NoteAdjusted diluted earnings per share of $2.95 to $3.05

Capital returns

  • Deployed ~$200 million towards share repurchases, representing ~3 million shares or ~1% of diluted shares outstanding.
  • Completed ~$200 million of share repurchases in Q2, bringing total share repurchases over the last four quarters to ~$2 billion, representing ~38 million shares or ~11% of shares outstanding.

What drove it

  • Q2 reported revenue grew 7.9% year-over-year on a reported basis and 6.7% on a core basis.
  • Intelligent Operating Solutions revenue grew 8.8% / 7.4% (reported / core).
  • Advanced Healthcare Solutions revenue grew 6.0% / 5.3% (reported / core).
  • The company cited early evidence that investments in innovation acceleration, commercial acceleration, and recurring customer value are contributing to improved growth and earnings performance.
  • The company completed the separation of its former Precision Technologies segment on June 28, 2025; amounts in the release refer to continuing operations unless otherwise indicated.

Concerns

  • Advanced Healthcare Solutions adjusted EBITDA margin was 26.1%, versus 26.9% in Q2-25, a change of (80) bps.
  • The filing identifies risks including deterioration or instability in the economy and markets served, tariffs and trade restrictions, supply chain constraints, currency exchange rates, changes in tax rates and liabilities, debt obligations, and adverse effects of restructuring activities.

What to watch

  • Execution against FY 2026 adjusted diluted earnings per share guidance of $2.95 to $3.05.
  • Sustainability of 6.7% core revenue growth.
  • Advanced Healthcare Solutions adjusted EBITDA margin following the (80) bps year-over-year change.
  • Further deployment of capital toward share repurchases and the company’s focus on best relative returns.
  • Progress on the Fortive Accelerated strategy, including innovation acceleration, commercial acceleration, and recurring customer value.

Balance sheet and cash flow

  • GAAP operating cash flow of $299 million.
  • Free cash flow of $271 million.
  • Trailing Twelve Months (TTM) GAAP operating cash flow of $1,158M.
  • TTM free cash flow of $1,044M.

Analysis

Fortive reported a strong second quarter from continuing operations. Revenue was $1,097M, up 7.9% year-over-year on a reported basis, with 6.7% core revenue growth. GAAP net earnings rose 40.9% to $157M and GAAP diluted earnings per share rose 54.5% to $0.51. Adjusted EBITDA increased 12.0% to $323M, while adjusted diluted earnings per share increased 28.5% to $0.74.

Both reported segments grew. Intelligent Operating Solutions delivered $758M of revenue, up 8.8% / 7.4% on a reported / core basis, and its GAAP operating margin expanded 230 bps to 26.8%. Its adjusted EBITDA margin expanded 110 bps to 34.9%. Advanced Healthcare Solutions generated $339M of revenue, up 6.0% / 5.3% on a reported / core basis. Its GAAP operating margin increased 10 bps to 11.3%, but adjusted EBITDA margin declined (80) bps to 26.1%.

Profitability and cash conversion improved versus Q2-25. GAAP net earnings margin was 14.3%, compared with 11.0%, and adjusted EBITDA margin was 29.5%, compared with 28.4%. GAAP operating cash flow was $299M and free cash flow was $271M, with both up more than 45% year-over-year. TTM GAAP operating cash flow was $1,158M and TTM free cash flow was $1,044M.

Capital allocation remained focused on repurchases. Fortive deployed ~$200 million toward share repurchases in Q2, representing ~3 million shares or ~1% of diluted shares outstanding. The company stated that repurchases over the last four quarters totaled ~$2 billion, representing ~38 million shares or ~11% of shares outstanding.

Management raised FY 2026 adjusted diluted earnings per share guidance to $2.95 to $3.05, citing strong first-half performance and confidence in the business trajectory. The release does not provide revenue, gross margin, operating expense, tax-rate, or GAAP earnings guidance. The stated operational focus remains profitable organic growth acceleration, disciplined capital allocation, and investor trust, with management citing innovation acceleration, commercial acceleration, and recurring customer value as areas supporting growth and earnings performance.

Management, verbatim

Q2 marked another quarter of strong financial performance and execution by our team. Core revenue growth accelerated to 6.7%, adjusted EBITDA grew 12%, and adjusted EPS growth was 28% in the quarter.

Olumide Soroye, President and CEO

Looking ahead, we are raising our full-year 2026 adjusted EPS guidance range to $2.95 to $3.05, reflecting our strong first-half performance and confidence in the trajectory of the business.

Olumide Soroye, President and CEO

Not in the filing

stated, not guessed
  • Period-end date.
  • Consolidated GAAP gross profit and gross margin.
  • Consolidated GAAP operating income or operating margin.
  • Adjusted net earnings.
  • Cash balance.
  • Debt balance.
  • Dividend declaration or payment information.
  • Prior-quarter comparisons for reported metrics.
  • FY 2026 revenue guidance.
  • FY 2026 gross margin guidance.
  • FY 2026 operating expense guidance.
  • FY 2026 tax-rate guidance.
  • Prior FY 2026 guidance necessary to compare actual results with prior guidance.
  • Detailed CFO commentary.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about FTV earnings dates

When is Fortive's next earnings date?
AlphAI has no date for FTV yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.